pre-IPO PHARMA

COMPANY OVERVIEW

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.allaytx.com/


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 6, 2023

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors


Dec 13, 2022

No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants


Jan 27, 2022

Allay Therapeutics Appoints Ron Burch, M.D., Ph.D. to Scientific Advisory Board


Jan 6, 2022

Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore


Sep 15, 2021

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform


For More Press Releases


Google Analytics Alternative